CDK9 inhib 
Welcome,         Profile    Billing    Logout  
 26 Companies  20 Products   20 Products   267 Diseases   19 Trials   2308 News 
36 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
seliciclib (CYC202) / Cyclacel, Cedars-Sinai
2015-002911-13: A Phase II, dose ranging, multicenter, double-blind, placebo controlled study to evaluate safety and efficacy of (R)-roscovitine in subjects with Cystic Fibrosis.

Terminated
2
36
Europe
SELICICLIB, CYC202, Capsule
CHRU de Brest, PHRC
Cystic Fibrosis treated by 'roscovitine' in subjects homozygous for the F508del-CFTR mutation and chronically infected with Pseudomonas aeruginosa., Cystic Fibrosis treated by 'roscovitine', Diseases [C] - Respiratory Tract Diseases [C08]
 
 
NCT03774446: Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

Recruiting
2
13
US
Seliciclib, R-roscotivine
Cedars-Sinai Medical Center
Cushing Disease
08/26
08/26
voruciclib (ME-522) / MEI
NCT03547115: A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

Checkmark Data from trial for r/r B-cell malignancies or AML at ASH 2021
Nov 2021 - Nov 2021: Data from trial for r/r B-cell malignancies or AML at ASH 2021
Checkmark Initiation of combination trial in B cell malignancies
Jun 2018 - Jun 2018: Initiation of combination trial in B cell malignancies
Recruiting
1
100
US
voruciclib monotherapy, ME-522, voruciclib and venetoclax, VENCLEXTA®
MEI Pharma, Inc.
Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)
04/24
03/25
AT7519 / Novartis, Otsuka
NCT02503709: Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Completed
1
29
US
CDK Inhibitor AT7519, AT-7519, AT7519, AT7519M, CDK inhibitor AT7519M, Cyclin-Dependent Kinase Inhibitor AT7519M, Laboratory Biomarker Analysis, Onalespib, AT 13387, AT-13387, AT13387, Pharmacological Study
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Solid Neoplasm
08/20
10/20
zotiraciclib (TG02) / Cothera Biosci
NCT05588141: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

Recruiting
1/2
96
US
Zotiraciclib
National Cancer Institute (NCI)
Brain Tumor, Cancer
08/28
08/32
dinaciclib (MK-7965) / Merck (MSD)
S0826, NCT00937937: Dinaciclib in Treating Patients With Stage IV Melanoma

Checkmark P2 data - ASCO
Jun 2012 - Jun 2012: P2 data - ASCO
Active, not recruiting
2
72
US
Dinaciclib, CDK Inhibitor SCH 727965, MK 7965, MK-7965, MK7965, SCH 727965, SCH-727965, SCH727965
National Cancer Institute (NCI)
Acral Lentiginous Melanoma, Cutaneous Nodular Melanoma, Lentigo Maligna Melanoma, Low-CSD Melanoma, Mucosal Melanoma, Recurrent Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7
10/13
03/26
NCT02668731: Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Recruiting
1
60
US
Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Dinaciclib, CDK Inhibitor SCH 727965, SCH 727965, Laboratory Biomarker Analysis
Mayo Clinic, National Cancer Institute (NCI)
Recurrent Plasma Cell Myeloma
06/17
 
NCT01434316: Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors

Active, not recruiting
1
121
US
Dinaciclib, CDK Inhibitor SCH 727965, MK 7965, MK-7965, MK7965, SCH 727965, SCH-727965, SCH727965, Veliparib, ABT 888, ABT-888, ABT888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm
03/23
08/26
alvocidib (DSP-2033) / Sumitomo Pharma
NCT01413880: Alvocidib (Flavopiridol), Ara-C and Mitoxantrone (FLAM) Versus "7+3" for Newly (AML)

Active, not recruiting
2
165
US
FLAM, alvocidib, arC, novanrone, 7&3, ara-c, daunorubicin or idarubicin
Sidney Kimmel Comprehensive Cancer Center
Acute Myelogenous Leukemia
07/13
12/15
fadraciclib (CYC065) / Cyclacel
2021-002924-18: A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK2/9 Inhibitor, in Subjects With Advanced Solid Tumors and Lymphoma Estudio en fase I/II, abierto y multicéntrico para investigar la seguridad, farmacocinética y eficacia de fadraciclib (cyc065), un inhibidor de cdk2/9 oral, en sujetos con tumores sólidos avanzados y linfoma

Not yet recruiting
1/2
354
Europe
Fadraciclib, CYC065, Capsule, hard
Cyclacel Pharmaceuticals, Cyclacel Limited
Endometrial cancer, Ovarian cancer, Biliary tract cancer, Hepatocellular carcinoma, B-cell lymphoma, T-cell lymphoma, Metastatic colorectal cancer, Breast cancer (metastatic HER-2 refractory, Hormone receptor +, HER-2 negative, and MBC post-CDK4/6 inhibitor, Triple-negative)Basket cohort: tumor types that are suspected to have a related mechanism of action and are not included in previous groups Cáncer de endometrio, cáncer de ovario, cáncer de las vías biliares, carcinoma hepatocelular (CHC), linfoma de linfocitos B, linfoma de linfocitos T, cáncer colorrectal metastásico, cáncer de mama (HER-2 metastásico refractario, receptor hormonal +, HER-2 negativo e inhibidor de MBC post-CDK4 / 6, triple negativo)Cohorte de cesta: tipos de tumores que se sospecha que tienen un mecanismo de acción relacionado y no están incluido en los grupos anteriores, Endometrial cancer, Ovarian cancer, Biliary tract cancer, Hepatocellular carcinoma, B-cell lymphoma, T-cell lymphoma, Metastatic colorectal cancer, Breast cancer, Other solid tumors Cáncer de endometrio/ovario, cáncer de vías biliares, carcinoma hepatocelular, linfoma de linfocitos B, linfoma de linfocitos T, cáncer colorrectal metastásico, cáncer de mama, otros tumores sólidos., Diseases [C] - Cancer [C04]
 
 
CYC065-101, NCT04983810 / 2021-002924-18: A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma

Recruiting
1/2
330
Europe, US, RoW
Fadraciclib, CYC065
Cyclacel Pharmaceuticals, Inc., Cyclacel Limited
Solid Tumor, Adult, Lymphoma
04/25
06/25
NCT05168904: A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)

Suspended
1/2
210
US
fadraciclib, CYC065
Cyclacel Pharmaceuticals, Inc.
Leukemia, Myelodysplastic Syndrome(MDS)
10/24
12/24
ESMART, NCT02813135 / 2016-000133-40: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

Recruiting
1/2
472
Europe
Ribociclib, Kisqali, LEE011, Topotecan, Hycamtin, Temozolomide, Temodar, Everolimus, Afinitor, votubia, Adavosertib, AZD1775, Carboplatin, Paraplatin, Olaparib, Lynparza, Irinotecan, Camptosar, CPT-11, Vistusertib, AZD2014, Nivolumab, Opdivo, Cyclophosphamide, Cytoxan, Selumetinib, Koselugo, Enasidenib, Idhifa, Lirilumab, BMS-986015, Fadraciclib, CYC065, Cytarabine, Arabinosylcytosine, Cytosar-U, Dexamethasone, Decadron, Dexasone, Diodex, Hexadrol, Maxidex, Ceralasertib, AZD6738, Futibatinib, Tas-120, Capmatinib, Tabrecta, INC280, Avelumab, BAVENCIO, Peposertib, Capivasertib, TRUQAP, AZD5363, Vinorelbine, Navelbine
Gustave Roussy, Cancer Campus, Grand Paris, National Cancer Institute, France, Fight Kids Cancer, Fondation ARC
Pediatric Cancer
02/31
02/31
NCT03739554: CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

Completed
1
5
US
CYC065, Venetoclax, ABT-199
Cyclacel Pharmaceuticals, Inc.
Relapsed or Refractory Chronic Lymphocytic Leukemia
11/22
04/23
NCT02552953: A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers

Completed
1
60
US
CYC065
Cyclacel Pharmaceuticals, Inc.
Cancer
10/22
08/23
NCT04017546: CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS

Completed
1
14
US
CYC065, Venetoclax
Cyclacel Pharmaceuticals, Inc., M.D. Anderson Cancer Center
AML, MDS
11/22
04/23
NCT05817890: Absorption, Metabolism, and Excretion of CYC065 in Healthy Male Subjects

Completed
1
8
US
Fadraciclib, CYC065
Cyclacel Pharmaceuticals, Inc.
Healthy
02/24
05/24
zemirciclib (AZD4573) / AstraZeneca
2021-002570-54: AZD4573 as Monotherapy or in Combination with Anti-cancer Agents in Patients with r/r PTCL or r/r cHL AZD4573 in monoterapia o in combinazione con agenti antitumorali in pazienti con PTCL r/r o cHL r/r

Not yet recruiting
2
90
Europe
AZD4573, [AZD4573], Concentrate for solution for injection/infusion
ASTRAZENECA AB, AstraZeneca AB
- Relapsed/refractory Peripheral T-cell Lymphoma- Relapsed/refractory Classical Hodgkins Lymphoma - Linfoma a cellule T periferico recidivante/refrattario- Linfoma di Hodgkin classico recidivante/refrattario, Cancer (lymphoma) Cancro (linfoma), Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT05140382 / 2021-002570-54: AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL

Completed
2
52
Europe, US, RoW
AZD4573
AstraZeneca, AstraZeneca AB
Relapsed/Refractory Peripheral T-cell Lymphoma, Relapsed/Refractory Classical Hodgkins Lymphoma
08/23
02/24
NCT04630756 / 2020-001642-18: AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer

Completed
1/2
40
Europe, Canada, US, RoW
AZD4573, AZ13810325, Acalabrutinib, ACP-196 /Calquence
AstraZeneca, Parexel
Advanced Haematological Malignancies
09/23
02/25
enitociclib (VIP152) / Vincerx
NCT05371054: Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

Active, not recruiting
1/2
8
US
Vysis LSI MYC Break Apart Rearrangement Probe Kit, Venetoclax, Venclexta, Venclyxto, VIP152, Enitociclib, Prednisone, Rayos, Deltasone, Prednisone Intensol, PET, Positron emission imaging, EKG, Electrocardiogram, ECHO, Echocardiogram, CT neck chest, abdomen, and pelvis, Computed tomography neck chest, abdomen, and pelvis, MRI, Magnetic resonance imaging, Bone marrow aspiration/Biopsy, BM aspiration/Bx
National Cancer Institute (NCI)
Lymphoma, Non-Hodgkin Lymphoma, NHL, Hematologic Malignancies, Lymphoid Malignancies
07/24
01/26
VNC-152-101, NCT02635672: Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

Completed
1
110
Europe, US, RoW
VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda, pembrolizumab, VIP152 (BAY 1251152) 15 mg
Vincerx Pharma, Inc.
Neoplasms
11/24
11/24
VNC-152-102, NCT04978779: A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

Terminated
1
6
Europe, US
VIP152, BTKi
Vincerx Pharma, Inc.
Relapsed Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Richter Syndrome, MYC Amplification, MYC Overexpression, MYC Translocation
05/23
05/23
TP-1287 / Sumitomo Pharma
NCT03604783: Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors

Terminated
1
74
US
TP-1287
Sumitomo Pharma America, Inc.
Advanced Solid Tumors, Sarcoma, Ewing Sarcoma, Dedifferentiated Liposarcoma, Synovial Sarcoma
01/24
01/24
BTX-A51 / Edgewood Oncology
NCT04243785: A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Recruiting
1
80
US
BTX-A51, Azacitidine
Edgewood Oncology Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome
03/26
03/27
BTX-A51-002, NCT04872166: A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

Recruiting
1
112
US
BTX-A51
Edgewood Oncology Inc.
Advanced Solid Tumor, Metastatic Breast Cancer
05/26
05/27
NCT06414434: BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma

Recruiting
1
24
US
BTX-A51, C32H41ClN6O6S2, (1r,4r)-N 1-(5-chloro-4-(5-(cyclopropylmethyl)-1-methyl-l H pyrazol-3-yl)pyrimidin-2-yl)cyclohexane-l ,4-diamine bis(4-methylbenzenesulfonate),
Michael Wagner, MD, Edgewood Oncology Inc.
Liposarcoma, Recurrent Liposarcoma, Metastatic Liposarcoma, Unresectable Liposarcoma, MDM2 Gene Amplification, Myxoid Liposarcoma, CIC-Rearranged Sarcoma
06/26
06/27
istisociclib (KB-0742) / Ignota Labs
KB-0742-1001, NCT04718675: A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)

Terminated
1/2
135
Europe, US
KB-0742
Kronos Bio
Relapsed Solid Tumors, Refractory Solid Tumors, Non-Hodgkin Lymphoma, HGSOC, Platinum Resistant High Grade Serous Ovarian Cancer
01/25
02/25
tambiciclib (SLS009) / SELLAS Life Sciences
NCT06375733: A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL

Recruiting
1/2
51
RoW
GFH009, Zanubrutinib
Genfleet Therapeutics (Shanghai) Inc.
Large B-cell Lymphoma
12/26
12/26
GFH009X2101, NCT04588922: Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies

Recruiting
1/2
160
US, RoW
SLS009, GFH009, venetoclax, Venclexta, azacitidine, Vidaza, azacytidine
Sellas Life Sciences Group, Sellas Life Sciences Group
Hematologic Malignancies
12/25
12/25
NCT05934513: A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Recruiting
1/2
95
RoW
GFH009
Genfleet Therapeutics (Shanghai) Inc.
Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
12/25
06/26
PRT2527 / Prelude Therap
NCT05159518: A Study of PRT2527 in Participants With Advanced Solid Tumors

Completed
1
30
US
PRT2527
Prelude Therapeutics
Sarcoma, Castrate Resistant Prostate Cancer, Hormone Receptor Positive HER2 Negative Breast Cancer, Non-small Cell Lung Cancer, Solid Tumors With Known MYC Amplification
12/23
12/23
PRT2527-02, NCT05665530: A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

Active, not recruiting
1
86
Europe, Canada, US, RoW
PRT2527, Zanubrutinib, Venetoclax
Prelude Therapeutics, BeiGene
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Mantle Cell Lymphoma (MCL), Richter's Syndrome, T-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma, Myeloid Malignancies, Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome (MDS), MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome
06/25
03/26
SYHX1903 / CSPC Pharma
NCT05055791: A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies

Not yet recruiting
1/2
312
NA
SYHX1903
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma
06/26
09/26
sunaciclib (AU-07) / Qianhong Bio-Pharma, Aucentra
QH-RD107-02-01, NCT06532058: Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
2
53
RoW
QHRD107 capsule，Venclexta and Azacitidine, CDK9 inhibitors
Changzhou Qianhong Bio-pharma Co., Ltd.
Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML)
02/25
05/25
CTR20190521: Clinical study on the safety of QHRD107 capsules

Completed
1
24
China
QHRD107 - Qianhong Bio-Pharma
Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd.
Acute myeloid leukemia (AML)
 
 
TT001 / Ting Therap
No trials found
NEOS-518 / NeoSome Life Sci
No trials found
RP16035 / Rhizen
No trials found
SLX 3030 / Biolexis Therap
No trials found
YK-2168 / Damei Biopharma, WuXi AppTec
No trials found

Download Options